These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 30615313)

  • 21. Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model.
    Freeman LM; Lam A; Petcu E; Smith R; Salajegheh A; Diamond P; Zannettino A; Evdokiou A; Luff J; Wong PF; Khalil D; Waterhouse N; Vari F; Rice AM; Catley L; Hart DN; Vuckovic S
    J Immunol; 2011 Oct; 187(8):3987-96. PubMed ID: 21908738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Establishment of xenotransplated mouse model using primary multiple myeloma cells].
    Liu CY; Zhang L; Wang N; Wang D; Geng Z; Xu DM; Li CR; Zhou JF; Huang L
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):195-9. PubMed ID: 22781606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mouse myeloma system. A model for studying the effect of malignant transformation on immunoglobulin production.
    Baumal R; Percy M
    Isr J Med Sci; 1977 Aug; 13(8):777-96. PubMed ID: 408295
    [No Abstract]   [Full Text] [Related]  

  • 24. Cellular immunotherapy in multiple myeloma: lessons from preclinical models.
    Binsfeld M; Fostier K; Muller J; Baron F; Schots R; Beguin Y; Heusschen R; Caers J
    Biochim Biophys Acta; 2014 Dec; 1846(2):392-404. PubMed ID: 25109893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
    Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
    Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.
    Cooke RE; Gherardin NA; Harrison SJ; Quach H; Godfrey DI; Prince M; Koldej R; Ritchie DS
    J Transl Med; 2016 Sep; 14(1):259. PubMed ID: 27599546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
    Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
    Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
    Libouban H; Onno C; Pascaretti-Grizon F; Gallois Y; Moreau MF; Baslé MF; Chappard D
    Leuk Res; 2006 Nov; 30(11):1371-5. PubMed ID: 16814861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse plasmacytoma: an experimental model of human multiple myeloma.
    Gadó K; Silva S; Pálóczi K; Domján G; Falus A
    Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma.
    Timm MM; Kimlinger TK; Haug JL; Kline MP; Greipp PR; Rajkumar SV; Kumar SK
    Leukemia; 2006 Oct; 20(10):1863-9. PubMed ID: 16932343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
    Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
    Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental plasmacytomas in relation to human multiple myeloma.
    Azar HA
    Ann Clin Lab Sci; 1974; 4(3):157-63. PubMed ID: 4825619
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
    Yu W; Chen Y; Xiang R; Xu W; Wang Y; Tong J; Zhang N; Wu Y; Yan H
    Leuk Lymphoma; 2017 Feb; 58(2):428-437. PubMed ID: 27439454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
    Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K
    Am J Pathol; 2004 Sep; 165(3):869-78. PubMed ID: 15331411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
    Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
    Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.